SCHEMBL953764

SCHEMBL953764

COc1cccc(OC)c1-c1nc(-c2c(C)nn3ccccc23)sc1C(N)=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 3/20 0.37
NEK2 P51955 1/20 0.37
CDC7 O00311 2/20 0.35
CCNE1 P24864 2/20 0.35
CDK2 P24941 2/20 0.35
DBF4 Q9UBU7 2/20 0.35
GAA P10253 2/20 0.35
ALDH1A1 P00352 2/20 0.35
HPGD P15428 2/20 0.35
HSD17B10 Q99714 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
HIF1A Q16665 1/20 0.34
HTT P42858 1/20 0.34
ATM Q13315 1/20 0.34
MAPT P10636 3/20 0.33
KMT2A Q03164 2/20 0.33
TSHR P16473 1/20 0.33
MAPK1 P28482 1/20 0.33
MEN1 O00255 1/20 0.33
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL955283 0.93 CDC7 (0.36) PLK1NEK2CDC7CCNE1CDK2
SCHEMBL953959 0.93 KMT2A (0.39) PLK1NEK2CDC7CCNE1CDK2
SCHEMBL954019 0.91 HTT (0.39) PLK1NEK2CDC7CCNE1CDK2
SCHEMBL956093 0.91 SMN1; SMN2 (0.38) CDC7DBF4ALDH1A1HPGDHIF1A
SCHEMBL957443 0.90 TSHR (0.39) GAAALDH1A1HPGDHSD17B10HIF1A
SCHEMBL952868 0.89 CDC7 (0.36) PLK1NEK2CDC7CCNE1CDK2
SCHEMBL953497 0.89 CDC7 (0.39) PLK1CDC7CCNE1CDK2DBF4
SCHEMBL955010 0.86 CDC7 (0.40) PLK1CDC7CCNE1CDK2DBF4
SCHEMBL956374 0.85 KMT2A (0.39) GAAALDH1A1HPGDHSD17B10HTT
SCHEMBL953922 0.85 MAP4K1 (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9139589-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-09-22 US disclosed
US-9090601-B2 Thiazole derivatives MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-07-28 US disclosed
EP-2391619-A1 HETEROARYLS AND THEIR USE AS PI3K INHIBITORS Millennium Pharmaceuticals, Inc. (US) 2011-12-07 EP disclosed
US-20110003807-A1 Thiazole derivatives MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed
US-20110003806-A1 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed
WO-2010090716-A1 HETEROARYLS AND THEIR USE AS PI3K INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003807-A1 Thiazole derivatives MTOR, RICTOR, AKT2 PLK1 558/4885NEK2 851/4885CDC7 601/4885
US-20110003806-A1 Heteroaryls and uses thereof RICTOR, MTOR, AKT1S1 PLK1 1770/4885NEK2 1909/4885CDC7 1063/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.